0001237899-20-000016.txt : 20200413 0001237899-20-000016.hdr.sgml : 20200413 20200413192331 ACCESSION NUMBER: 0001237899-20-000016 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200409 FILED AS OF DATE: 20200413 DATE AS OF CHANGE: 20200413 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Landry Robert E CENTRAL INDEX KEY: 0001585160 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 20789687 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2020-04-09 0 0000872589 REGENERON PHARMACEUTICALS, INC. REGN 0001585160 Landry Robert E 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 0 1 0 0 EVP Finance CFO Common Stock 2020-04-09 4 M 0 3500 272.7 A 27873 D Common Stock 2020-04-09 4 F 0 2672 508.25 D 25201 D Common Stock 2020-04-13 4 S 0 99 505.6 D 25102 D Common Stock 2020-04-13 4 S 0 38 506.24 D 25064 D Common Stock 2020-04-13 4 S 0 30 507.45 D 25034 D Common Stock 2020-04-13 4 S 0 115 508.54 D 24919 D Common Stock 2020-04-13 4 S 0 170 509.45 D 24749 D Common Stock 2020-04-13 4 S 0 143 510.43 D 24606 D Common Stock 2020-04-13 4 S 0 156 511.59 D 24450 D Common Stock 2020-04-13 4 S 0 31 512.58 D 24419 D Common Stock 2020-04-13 4 S 0 46 517.71 D 24373 D Common Stock 172 I By 401(k) Plan Non-Qualified Stock Option (right to buy) 272.7 2020-04-09 4 M 0 3500 0.0 D 2023-09-09 Common Stock 3500 39000 D Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Represents volume-weighted average price of sales of 30 shares of Company stock on April 13, 2020 at prices ranging from $507.44 to $507.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 13, 2020 at each separate price. Represents volume-weighted average price of sales of 115 shares of Company stock on April 13, 2020 at prices ranging from $508.24 to $508.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 13, 2020 at each separate price. Represents volume-weighted average price of sales of 170 shares of Company stock on April 13, 2020 at prices ranging from $509.03 to $509.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 13, 2020 at each separate price. Represents volume-weighted average price of sales of 143 shares of Company stock on April 13, 2020 at prices ranging from $510.11 to $510.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 13, 2020 at each separate price. Represents volume-weighted average price of sales of 156 shares of Company stock on April 13, 2020 at prices ranging from $511.23 to $511.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 13, 2020 at each separate price. Represents volume-weighted average price of sales of 31 shares of Company stock on April 13, 2020 at prices ranging from $512.01 to $512.62. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 13, 2020 at each separate price. The stock option award vests in four equal annual installments, commencing one year after the date of grant. /s/**Robert E. Landry 2020-04-20